MedPage Today on MSN
Ultra-Rare Mitochondrial Disease Gets First FDA-Approved Drug
T he FDA approved doxecitine and doxribtimine powder (Kygevvi) for thymidine kinase 2 deficiency (TK2d), an ultra-rare ...
Rybelsus is now FDA-approved for managing cardiovascular health. Doctors say oral GLP-1s may reduce heart attack and stroke ...
A new drug, crisugabalin, has been approved in other countries but is not yet available in the United States. It has shown ...
Anime giant Crunchyroll has partnered with Luminopia, a digital health company that devises new treatments for significant ...
The FDA-approved drug Pluvicto offers hope for advanced prostate cancer patients, but access barriers remain despite proven ...
In October 2025, the U.S. Food and Drug Administration (FDA) granted approval to multiple new cancer therapies and supportive care options, covering treatments for acute myeloid leukemia (AML), ...
5don MSN
FDA to streamline approvals for generic biological drugs in latest move targeting health costs
The US Food and Drug Administration will take steps to streamline the process to develop generic versions of complex biological drugs, the agency announced Wednesday. The changes are meant to ...
FDA feedback enables CervoMed to proceed with proposed endpoints, patient enrichment strategy, and other key aspects of Phase 3 trial design to support potential New Drug Application CervoMed is ...
The Food and Drug Administration (FDA) is launching an effort to streamline the approval process for cheaper alternative “biosimilar” versions of biologic drugs as a way to curb health costs.  The ...
There are strict rules about what drug companies can say in TV or print ads. But a new study shows there's a lot more wiggle room when companies pay to sponsor online search results.
FOX 26 Houston on MSN
FDA approved eye drop can help people regain near vision
HOUSTON - Vizz eye drops are designed for individuals with good distance vision who struggle with near vision. They work by ...
After discussions with the FDA, Nuvation disclosed that it has “decided not to pursue a head-to-head randomized study of safusidenib against vorasidenib to support approval in non-enhancing grade 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results